SM-130686 | 259666-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: SM-130686
• 英文别名: (3S)-3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3-hydroxy-2-oxo-4-(trifluoromethyl)indole-6-carboxamide
• CAS: 259666-71-2
• 化学式: C₂₂H₂₃ClF₃N₃O₃
• 分子量: 469.891
• InChiKey: YSSPGXCFFITNCE-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  SM-130686 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以10.4 mg的产率得到SM 130686
  参考文献：
  名称：

  Tomita, Daisuke; Yamatsugu, Kenzo; Kanai, Motomu, Journal of the American Chemical Society, 2009, vol. 131, p. 6946 - 6948

  摘要：

  DOI：
• 作为产物：
  描述：

  间硝基三氟甲苯 在 氢氧化钾 、 N-碘代丁二酰亚胺 、 四(三苯基膦)钯 、 硫酸 、 tin(ll) chloride 作用下， 以 乙醚 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 、 叔丁醇 为溶剂， 反应 11.33h， 生成 SM-130686
  参考文献：
  名称：

  羟吲哚衍生物作为口服活性强效生长激素促分泌素。

  摘要：

  合成了一系列取代的羟吲哚衍生物，并使用培养的大鼠垂体细胞评估了生长激素（GH）的释放活性。发现（+）-6-氨基甲酰基-3-（2-氯苯基）-（2-二乙基氨基乙基）-4-三氟甲基氧吲哚（SM-130686，37S）具有强活性（EC（50）= 3.0 nM），而其他对映异构体37R的活性降低。X射线晶体学分析证实了37S的绝对构型。化合物37S在大鼠中表现出良好的药代动力学特征，在10 mg / kg的口服生物利用度为28％，并且具有出色的体内活性，如每天两次以10 mg / kg的口服给药4天后体重明显增加所证明。化合物37S取代了（35）S-MK-677与人GHS-R的结合，IC（50）值为1.2 +/- 0.2 nM。

  DOI：

  10.1021/jm0103763

文献信息

• Method of reducing C-reactive protein using growth hormone secretagogues
  申请人：Polvino J. William

  公开号：US20050261201A1

  公开（公告）日：2005-11-24

  The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event is a cardiovascular event (e.g., myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (e.g., stroke (such as transient ischemic attacks (TIAs)). In yet another embodiment the vascular event is a peripheral vascular event (e.g., intermittent claudication). The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be coadministered with a second growth hormone secretagogue, HMG CoA reductase inhibitor, an ACAT inhibitor, a CETP inhibitor, an anti-inflammatory agent, an ACE inhibitor, a Beta blocker, a cholesterol absorption inhibitor, a nicotonic acid, a fibric acid derivative, a bile acid sequestering agent or a combination thereof.
• Growth-Hormone Secretagogues
  申请人：Geesaman Bard J.

  公开号：US20080261873A1

  公开（公告）日：2008-10-23

  Disclosed are methods of treating a disorder of the stomach, intestine or duodenum in a human subject. The method includes administering to the subject, a pharmaceutical composition comprising a compound that increases gastrointestinal motility (e.g., by modulating myenteric nerve activity) and/or induces the secretion or production of growth hormone.
• PEPTIDOMIMETIC MACROCYCLES
  申请人：Aileron Therapeutics, Inc.

  公开号：US20170037105A1

  公开（公告）日：2017-02-09

  The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
• METHODS OF TREATING NEURODEGENERATIVE CONDITIONS
  申请人：Oxeia Biopharmaceuticals, Inc.

  公开号：US20170121385A1

  公开（公告）日：2017-05-04

  The present disclosure provides methods for treating a neurodegenerative condition or situation in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising ghrelin or a ghrelin variant.
• METHODS OF TREATING TRAUMATIC BRAIN INJURY
  申请人：OXEIA BIOPHARMACEUTICALS, INC.

  公开号：US20170266257A1

  公开（公告）日：2017-09-21

  The present disclosure provides methods for treating traumatic brain injury and other neurological disorders in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising ghrelin or a ghrelin variant. This invention provides for methods for treating a severe or moderate traumatic brain injury in a patient wherein said method comprises administering to the subject suffering from said severe or moderate traumatic brain injury a therapeutic effective amount of ghrelin or a ghrelin variant or a composition comprising ghrelin or a ghrelin variant so as to treat said severe or moderate traumatic brain injury.